Hepatic steatosis as a possible risk factor for the development of hepatocellular carcinoma after eradication of hepatitis C virus with antiviral therapy in patients with chronic hepatitis C

doi:10.3748/wjg.v13.i39.5180

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 13, Issue 39

This Article

Citation of this article

Corresponding Author of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (2432)

All Articles published online

The chart showing PDF series, HTML series, Figures (1-3) series, Tables (1-2) series.

Item

Count

PDF

314

HTML

1652

Figures (1-3)

254

Tables (1-2)

212

Sum=2432

Oct 21, 2007 (publication date) through Jan 5, 2025

Times Cited of This Article

Times Cited (63)

Journal Information of This Article

Publication Name

World Journal of Gastroenterology

ISSN

1007-9327

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Liver Cancer

World J Gastroenterol. Oct 21, 2007; 13(39): 5180-5187
Published online Oct 21, 2007. doi: 10.3748/wjg.v13.i39.5180

Table 1 Viral, clinical and histopathological profiles of patients with SVR who developed HCC

	Age/sex	HCV genotype	Pre-IFN treatment				Occurrence of HCC			Duration until HCC (yr)
	Age/sex	HCV genotype	ALT (IU/L)	Fibrosis	Steatosis	BMI	Fibrosis	Steatosis	BMI	Duration until HCC (yr)
Case 1	67/M	1b	138	F3	Grade 2	28.4	F2	Grade 1	27.4	5.4
Case 2	58/M	2a	39	F1	Grade 1	23.5	F2	Grade 0	22.5	9.5
Case 3	68/M	n.t.	111	F4	Grade 2	24.2	F2	Grade 2	25.0	9.6
Case 4	53/M	1b	82	F2	Grade 1	19.6	NT	NT	20.3	8.4
Case 5	58/M	1b	21	F3	Grade 1	23.5	NT	NT	24.8	3.3
Case 6	65/F	2a	145	F3	Grade 1	25.6	F2	Grade 1	26.7	2.9
Case 7	54/M	1b	85	F2	Grade 2	26.1	F2	Grade 1	22.4	4.9

NT: Not tested; BMI: Body mass index. In cases 4 and 5, the liver tissues with the occurrence of HCC were not obtained because HCC was not treated with surgical operation.

Table 2 Pre-IFN viral, clinical and histopathological profiles of all patients with SVR

	Age (mean ± SD)	Sex (M/F)	ALT (IU) (mean ± SD)	Genotype (1/2/NT)	Hepatic fibrosis (F1/F2/F3/F4/NT)	Hepatic steatosis (Grade 0/1/2/3/NT)
All (n = 266)	46.3 ± 14.3	184/82	112 ± 99	102/142/20	103/99/28/8/28	116/95/19/1/35
HCC (n = 7)	60.4 ± 6.2	6/1	89 ± 47	4/2/1	1/2/3/1/0	0/4/3/0/0
No HCC (n = 259)	44.8 ± 13.3	178/81	113 ± 100	98/140/19	102/97/25/7/28	116/91/16/1/35

NT: Not tested.

Citation: Tanaka A, Uegaki S, Kurihara H, Aida K, Mikami M, Nagashima I, Shiga J, Takikawa H. Hepatic steatosis as a possible risk factor for the development of hepatocellular carcinoma after eradication of hepatitis C virus with antiviral therapy in patients with chronic hepatitis C. World J Gastroenterol 2007; 13(39): 5180-5187
URL: https://www.wjgnet.com/1007-9327/full/v13/i39/5180.htm
DOI: https://dx.doi.org/10.3748/wjg.v13.i39.5180